Welcome to the
Study of Chronic Pancreatitis, Diabetes and
Pancreatic Cancer (CPDPC)
Research Consortia
Welcome to the
Study of Chronic Pancreatitis, Diabetes and
Pancreatic Cancer (CPDPC)
Research Consortia
Research Objective
The overriding two objectives of this research program are to pursue clinical research on Chronic Pancreatitis (including those with Acute Recurrent Pancreatitis, ARP), by identifying and characterizing a large cohort of pediatric and adult patients with CP and ARP to encourage translational research focusing upon elucidating the pathogenesis that will provide the basis for understanding the natural history and developing means of diagnosis, treatment and clinical management of Chronic Pancreatitis and its sequela: chronic pain, pancreatic insufficiency and on pancreatic cancer and pancreatogenic Diabetes Mellitus (T3cDM) and their pathogenic interrelationships, by identifying and following a cohort of newly diagnosed diabetic patients in the setting of Cancer Prevention.
Research results are shared freely within Consortium to develop trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the Clinical Centers.
The Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) was formed to undertake a comprehensive clinical, epidemiological, and biological characterization of patients with Chronic Pancreatitis (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association.
The multidisciplinary teams will also undertake studies on the development of pancreatic cancer in newly diagnosed diabetic patientse.
On Chronic Pancreatitis (including those with Acute Recurrent pancreatitis, ARP), by identifying and characterizing a large cohort of pediatric and adult patients with CP and ARP to encourage translational research focusing upon elucidating the pathogenesis that will provide the basis for understanding the natural history and developing means of diagnosis, treatment and clinical management of Chronic Pancreatitis and its sequela: chronic pain, pancreatic insufficiency and on pancreatic cancer and pancreatogenic Diabetes Mellitus (T3cDM) and their pathogenic interrelationships, by identifying and following a cohort of newly diagnosed diabetic patients in the setting of Cancer Prevention.
Research and Initiatives
Grantor Organizations
The National Institutes of Health (NIH) distributes funding to the following organizations through congressional appropriations. The organization's leadership, guided by the mission set by the nation's scientists, evaluates applications and grants funds to organizations with the mission, goals, expertise and resources to carry out the research initiatives set forth by the needs of the American People and the World for cancer research.
Awardee Organizations
Our consortium is comprised of the following organizations awarded research programs by the National Cancer Institute (NCI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which are funded by way of the National Institutes of Health (NIH) using appropriations budgeted by the United States Congress.
Learn more about each awardee organization, the Principal Investigators, and their research teams contributing to the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer.
Participating Cohort Organizations
In every multi-site research consortium, participating cohort organizations are very crucial to the overall success of the research. These organizations lend their leadership, expertise, and resources to support the specific aims of the various research centers, workgroups, and studies. Additionally, many contribute significantly to the leadership of the consortium by participating in committees that drive the various activities and initiatives.
Learn more about the participating cohort organizations contributing significantly to the research efforts associated with The Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer.
Multi-site research projects are essential within cancer research to help drive discovery when advancing medical treatments. Although the success of multi-site research is significantly dependent on clinical and organizational expertise, management, best practices for engagement, and data security is an essential part of research coordination.
The Coordinating and Data Management Centers (CDMCs) play a crucial role in managing and coordinating multi-site research projects funded by the National Institutes of Health (NIH). They serve as central hubs for various tasks, including:
-
Study Design and Implementation: Coordinating centers create rules and frameworks governing data collection, use, and dissemination. They also manage study design and implementation.
-
Data Management: Coordinating centers handle data coordination, ensuring accurate and efficient data collection, storage, and analysis.
-
Administrative Support: They assist with budget management, regulatory filings, site selection, investigator training, and form development.
-
Biostatistical Leadership: Coordinating centers provide expertise in statistical analysis, contributing to the success of multicenter research programs.
There are two primary types of coordinating centers:
-
Clinical Coordinating Centers (CCC): Responsible for clinical trial operations.
-
Data Coordinating Centers (DCC): Focus on statistics and data management functions. These centers enhance study efficiency, accelerate results, and facilitate impactful research.
Additionally, the following represent other keyways the Coordinating and Data Management Centers are design to support multi-site research project funded by the National Institutes of Health.
Multi-Site Research Programs
Coordinating and Data Management Centers
Data Management Center of Excellence (DMCOE)
The DMCOE focuses on collecting and assessing Findable, Accessible, Interoperable, and Reusable (FAIR) data management and sharing best practices. Its objectives include:
-
Assessing the current landscape of NIH-supported data repositories.
-
Gathering and distributing FAIR and data management resources to stakeholders both within and outside NIH.
-
Facilitating adoption of best practices through training and learning support.
Data Management and Coordinating Centers (DMCCs)
These centers provide infrastructure and research support for various NIH-funded networks and clinical trials. For example:
-
The DMCC supports a network of clinical sites, Diagnostic Centers of Excellence (DCoEs), and the Undiagnosed Diseases Program (UDP).
-
The DMCCs collaborate to harmonize data and workflows across multiple Common Fund programs, enabling cross-dataset analysis.
Clinical Trials Management
In the context of multi-site investigator-initiated clinical trials, the Data Coordinating Center (DCC) provides overall project coordination, administration, data management, and biostatistical support. It works closely with the collaborating Clinical Coordinating Center (CCC).
These centers ensure efficient data management, coordination, and collaboration across NIH projects, ultimately advancing scientific research and improving health outcomes.
The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training. NCI is deeply committed to the core values of equity, diversity, and inclusion that allow all staff to reach their potential and fully contribute to the institute’s cancer mission.
NCI Professional Judgement Authority
The National Cancer Act of 1971 gives the NCI Director special authority to submit an annual professional judgment budget directly to the President for review and delivery to Congress. This budget reflects NCI cancer research priorities and identifies areas of potential investment in cancer research.
Stage I
The White House Office of Management & Budget (OMB) coordinates with federal agencies to formulate the President's Budget, which covers all federal agencies, including the National Cancer Institute (NCI) and National Institutes of Health (NIH), and reflects the President's priorities. The President submits the budget to Congress, which must pass appropriations legislation that funds federal agencies.
Stage III
The appropriations committees finalize their legislative proposals, and the House and Senate consider the proposed legislation. Once passed and reconciled into a unified bill, Congress sends the legislation to the President.
Stage IV
The President signs the appropriations bill into law, making funds available to executive agencies, including National Cance Institute and the National Institutes of Health.
Stage II
The congressional appropriations committees consider the President's Budget as they prepare appropriations legislation for the next fiscal year.
The National Cancer Institute receives its funding, or appropriation, from Congress as part of the overall federal budget process. So, how does the National Institutes of Health and the National Cancer Institute receive funding for research projects?
How the National Cancer Institute (NCI) Receives Its Funding
Watch Driving Discovery, a video by the National Cancer Institute demonstrating how they drive the cancer research enterprise by supporting and convening researchers, paying for facilities and systems, coordinating the nation's cancer plan, and more for our joint cancer-related initiatives.
National Cancer Institute: Driving Discovery
The Department of Biostatistics at MD Anderson provides statistical collaboration, consultation, and quantitative research resources to clinical, laboratory, and prevention scientists, and engages in the planning, conduct, analysis, quality assurance, and interpretation of research studies. The faculty develop new statistical methodology to support cancer research: innovative clinical trial designs, Bayesian methods; longitudinal and survival data analysis; cancer screening and early detection; computer-intensive statistical methods for integrated high dimensional omics data analysis; functional, imaging, and biomarker data analysis; statistical modeling of observational processes; biological and medical informatics. The Department is supported by a Quantitative Research Computing (QRC) group, consisting of an Associate Director, 4 system and network administrators and a staff of 23 programmers who specialize in clinical trial software, data management, Bayesian numerical analysis, and bioinformatics and computational biology software engineering.
Coordinating and Data Management Center
Department and Expertise
The University of Texas MD Anderson Cancer Center is located within the Texas Medical Center, a 700-acre campus south of downtown Houston home to 46 not-for-profit institutions dedicated to providing the highest quality of medical care and conducting state-of-the-art research. MD Anderson Cancer Center provides world-class shared resources such as the Clinical and Translational Research Center, Research Animal Support Facility, Tissue Biospecimen and Pathology Resource, RNA sequencing facilities, and many others under the auspices of the Cancer Center Support Grant. MD Anderson is also home to the Institute for Personalized Cancer Therapy, dedicated to discovering biomarkers that predict treatment response and mechanisms of acquired resistance.
Coordinating and Data Management Center
Facilities and Resources
Coordinating and Data Management Center
Principal Investigators
Project Abstract
The proposed study is highly relevant to public health because pancreatic cancer is the 4th largest killer among all cancers yet, there are no effective ways for prevention or detection at a curable stage. Understanding the complex relationships between chronic pancreatitis, new-onset diabetes, and pancreatic cancer holds the key to finding effective interventions. Rigorous evaluation of the molecular basis for chronic pancreatitis, new-onset diabetes, and pancreatic cancer will lead to effective interventions and is therefore imperative for public health.
Public Health Relevance Statement
Coordinating and Data Management Center
NIH Project Information
A key to the success of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (Consortium) lies in effective communication and collaboration among scientists in multiple disciplines; strong study design for discovery and validation of biomarkers characterizing complex interactions between chronic pancreatitis (CP), diabetes mellitus (DM), and pancreatic cancer (PC) and evaluation of novel intervention strategies; and rigorous study execution of Consortium collaborative protocols.
The overall aims of the proposed Coordination and Data Management Center (CDMC) are to:
-
Provide coordination of the Consortium to enhance communication and collaboration among Consortium investigators and with the larger scientific communities;
-
Provide scientific and statistical leadership for the Consortium in research strategy, study design approaches, and statistical and computational methods; and,
-
Coordinate Consortium collaborative studies.
Under the direction of the Consortium Steering Committee (SC), the CDMC will:
-
Perform network coordination and promote collaborations among scientific investigators by providing support for Consortium meetings, SC, subcommittees, and Data Safety and Monitoring Board, developing and maintaining Consortium-secured websites and listservs, and producing and maintaining all Consortium documents;
-
Promote and develop proper study design approaches and analysis strategies for Consortium studies, provide statistical software to implement these strategies, provide statistical and computational support for Consortium collaborative studies, apply or develop novel statistical methods relevant to Consortium needs, in particular methods for dynamic prediction of PDAC risk in the Consortium cohort, methods for handling informative censoring in the Consortium cohort, and methods for group sequential biomarker evaluations; and
-
Support Consortium collaborative studies by developing and maintaining the study data management system, working with Consortium investigators on study design, protocol development, data forms, and study manuals; coordinating and monitoring studies; tracking specimens; and performing QA/QC and study evaluation; providing input on appropriate interpretation of study findings and reports; supporting the formation of distribution of Consortium biospecimen repositories; support preparations of documentations to FDA for Consortium INDs/IVDs, and providing a mechanism for rapid and routine information sharing among Consortium investigators and NIDDK/NCI staff.
The Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) was formed to undertake a comprehensive clinical, epidemiological, and biological characterization of patients with Chronic Pancreatitis including those with Acute Recurrent Pancreatitis or ARP.
Research Goal
Types of
Cancer Research
Basic Research seeks to understand the fundamental aspects of nature. It provides the foundation for advances against cancer.
Basic Research
Clinical Research tests drugs, medical devices, or other interventions in human volunteers to improve aspects of patient care.
Clinical Research
Population-based research explores the cause of cancer, cancer trends, and factors that affect the delivery and outcomes of cancer care in specific populations.
Population-Based Research
Translational Research moves basic research findings into clinic and clinic research findings into everyday care. In turn, results from clinical and population-based studies can guide basic research.
Translational Research
The University of Texas MD Anderson Cancer Center is honored to be designated as the Coordinating and Data Management Center (CDMC) by the National Institute of Diabetes and Digestive and Kidney Diseases and National Cancer Institute for the study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) Research Consortia.
This honor aligns with our mission to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research, and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees, and the public.
